Latest Options News

Regal Investment Fund has announced an estimated ordinary dividend of AUD 0.12 per unit for the half-year ending December 2025, alongside a full Dividend Reinvestment Plan available to eligible investors.

High-Tech Metals has intersected visible gold in multiple zones at its Wagtail deposit, advancing drilling and development efforts toward a potential near-term mining decision.

Tartana Minerals has received $1 million from a new investor as part of a $1.275 million placement, setting the stage for debt reduction and upcoming shareholder decisions.

Neuren Pharmaceuticals has secured Health Canada approval to expand its pivotal Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome into Canadian sites, complementing ongoing US enrolment.

The Northern Finland Administrative Court has overturned Kingsrose Mining’s exploration permit for the Penikat Project due to procedural errors by the regulator, delaying planned drilling until at least April 2026. Kingsrose remains confident in the project’s long-term potential despite the setback.

Midas Minerals has completed its acquisition of the Otavi Copper Project in Namibia, initiating multiple drilling programs across high-grade deposits and securing strong funding to drive exploration in 2026.

Waypoint REIT has secured a decade-long lease extension with Viva Energy Australia on 21 sites, boosting rental income by over 12% from August 2026. The REIT also strengthens its financial footing through key refinancing moves.

Cann Group Limited has launched a comprehensive suite of option offers aimed at raising incremental capital, subject to shareholder approval at a December 23 meeting. The prospectus outlines potential dilution and financial impacts as the company seeks to strengthen its balance sheet.

Pure One Corporation Limited is set to exit its 40% stake in Turquoise Group for AUD 5 million, securing a substantial profit and refocusing on its core clean energy ventures.

Mithril Silver and Gold accelerates exploration at its Copalquin gold-silver project with a third drill rig mobilized and a 25,000-metre drilling program planned for 2026, targeting multiple high-grade zones.

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics for US$4.8 billion includes Dimerix’s US licensing agreement, promising significant milestone payments and royalties. This deal strengthens Dimerix’s position as it advances its Phase 3 kidney disease therapy.

Lendlease has struck a binding agreement to sell a significant stake in its Malaysian TRX retail and office assets, marking a key step in its FY26 capital recycling strategy aimed at reducing gearing and unlocking value.